How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

Biagio Ricciuti, Alessia Mira, Elisa Andrini, Pietro Scaparone, Sandra Vietti Michelina, Federica Pecci, Luca Cantini, Andrea De Giglio, Giuseppe Lamberti, Chiara Ambrogio, Giulio Metro

Article Type

Review

Published

The authors review the current treatment landscape for patients with advanced non-small-cell lung cancers harbouring a KRAS G12C mutation, including PD-(L) 1-based therapies and direct KRAS inhibitors as well as sequential treatment options.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.